Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Phathom Pharmaceuticals (PHAT) Cost of Revenue: 2023-2025

Historic Cost of Revenue for Phathom Pharmaceuticals (PHAT) over the last 2 years, with Sep 2025 value amounting to $6.2 million.

  • Phathom Pharmaceuticals' Cost of Revenue rose 162.73% to $6.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $18.8 million, marking a year-over-year increase of 333.92%. This contributed to the annual value of $8.0 million for FY2024, which is 4674.25% up from last year.
  • As of Q3 2025, Phathom Pharmaceuticals' Cost of Revenue stood at $6.2 million, which was up 22.87% from $5.0 million recorded in Q2 2025.
  • Phathom Pharmaceuticals' Cost of Revenue's 5-year high stood at $6.2 million during Q3 2025, with a 5-year trough of $167,000 in Q4 2023.
  • Over the past 3 years, Phathom Pharmaceuticals' median Cost of Revenue value was $3.0 million (recorded in 2024), while the average stood at $2.9 million.
  • Data for Phathom Pharmaceuticals' Cost of Revenue shows a peak YoY surged of 2,184.43% (in 2024) over the last 5 years.
  • Phathom Pharmaceuticals' Cost of Revenue (Quarterly) stood at $167,000 in 2023, then skyrocketed by 2,184.43% to $3.8 million in 2024, then surged by 162.73% to $6.2 million in 2025.
  • Its last three reported values are $6.2 million in Q3 2025, $5.0 million for Q2 2025, and $3.7 million during Q1 2025.